Microbiome within Primary Tumor Tissue from Renal Cell Carcinoma May Be Associated with PD-L1 Expression of the Venous Tumor Thrombus
暂无分享,去创建一个
J. White | Yidong Chen | T. Johnson-Pais | D. Pruthi | M. Liss | Hanzhang Wang | R. Rodriguez | D. Kaushik | A. Mansour
[1] Yidong Chen,et al. Immunogenic Heterogeneity of Renal Cell Carcinoma With Venous Tumor Thrombus. , 2019, Urology.
[2] O. Kallioniemi,et al. Clonal heterogeneity influences drug responsiveness in renal cancer assessed by ex vivo drug testing of multiple patient‐derived cancer cells , 2018, International journal of cancer.
[3] J. López,et al. The Impact of Tumor Eco-Evolution in Renal Cell Carcinoma Sampling , 2018, Cancers.
[4] Zoltan Szallasi,et al. Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal , 2018, Cell.
[5] B. Helmink,et al. The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy. , 2018, Cancer cell.
[6] Laurence Zitvogel,et al. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors , 2018, Science.
[7] Julia L. Drewes,et al. High-resolution bacterial 16S rRNA gene profile meta-analysis and biofilm status reveal common colorectal cancer consortia , 2017, npj Biofilms and Microbiomes.
[8] J. Terzic,et al. The urinary microbiome associated with bladder cancer , 2017, bioRxiv.
[9] C. Fan,et al. Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma. , 2017, Cancer research.
[10] A. Eggermont,et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] Ling Xia,et al. Fusobacterium Nucleatum Subspecies Animalis Influences Proinflammatory Cytokine Expression and Monocyte Activation in Human Colorectal Tumors , 2017, Cancer Prevention Research.
[12] J. Bellmunt,et al. New treatment options for metastatic renal cell carcinoma , 2017, ESMO Open.
[13] P. Ascierto,et al. Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment , 2016, Oncotarget.
[14] A. Jemal,et al. Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.
[15] M. Lathrop,et al. Precision medicine from the renal cancer genome , 2016, Nature Reviews Nephrology.
[16] Arun Z. Thomas,et al. The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma , 2016, Therapeutic advances in urology.
[17] M. Kortylewski,et al. Stool Bacteriomic Profiling in Patients with Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor–Tyrosine Kinase Inhibitors , 2015, Clinical Cancer Research.
[18] V. Margulis,et al. Oncologic outcomes following surgical resection of renal cell carcinoma with inferior vena caval thrombus extending above the hepatic veins: a contemporary multicenter cohort. , 2014, The Journal of urology.
[19] Allyson L. Byrd,et al. Biogeography and individuality shape function in the human skin metagenome , 2014, Nature.
[20] Paul Theodor Pyl,et al. HTSeq—a Python framework to work with high-throughput sequencing data , 2014, bioRxiv.
[21] Björn Usadel,et al. Trimmomatic: a flexible trimmer for Illumina sequence data , 2014, Bioinform..
[22] M. Meng,et al. Natural history of untreated renal cell carcinoma with venous tumor thrombus. , 2013, Urologic oncology.
[23] Quinn Snell,et al. Pathoscope: Species identification and strain attribution with unassembled sequencing data , 2013, Genome research.
[24] Cole Trapnell,et al. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions , 2013, Genome Biology.
[25] Steven L Salzberg,et al. Fast gapped-read alignment with Bowtie 2 , 2012, Nature Methods.
[26] J. Brugarolas,et al. The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. , 2011, European urology.
[27] J. Brugarolas,et al. 1771 THE IMPACT OF TARGETED MOLECULAR THERAPIES ON THE LEVEL OF RENAL CELL CARCINOMA VENA CAVAL TUMOR THROMBUS , 2011 .
[28] M. Soloway,et al. Long-term survival in patients undergoing radical nephrectomy and inferior vena cava thrombectomy: single-center experience. , 2010, European urology.
[29] H. Sørensen,et al. The prognostic impact of comorbidities on renal cancer, 1995 to 2006: a Danish population based study. , 2009, The Journal of urology.
[30] K. Bensalah,et al. Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma. , 2009, European urology.
[31] S. Boyd,et al. Vena Caval Involvement by Renal Cell Carcinoma: Surgical Resection Provides Meaningful Long‐Term Survival , 1989, Annals of surgery.
[32] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.